Relmada Therapeutics Updates Principal Executive Offices
Ticker: RLMD · Form: 8-K · Filed: Sep 17, 2025 · CIK: 1553643
| Field | Detail |
|---|---|
| Company | Relmada Therapeutics, Inc. (RLMD) |
| Form Type | 8-K |
| Filed Date | Sep 17, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: administrative, address-change
Related Tickers: RLMD
TL;DR
Relmada moved offices, new address is 2222 Ponce de Leon Blvd, Coral Gables, FL.
AI Summary
Relmada Therapeutics, Inc. (RLMD) filed an 8-K on September 17, 2025, reporting its principal executive offices are located at 2222 Ponce de Leon Blvd., Floor 3, Coral Gables, FL 33134. The company's common stock trades on The NASDAQ Capital Market under the symbol RLMD. This filing primarily serves to update the company's address.
Why It Matters
This filing informs investors and stakeholders of the company's new operational base, which is crucial for communication and logistical purposes.
Risk Assessment
Risk Level: low — This is a routine administrative filing updating the company's address and does not involve financial or operational changes.
Key Players & Entities
- Relmada Therapeutics, Inc. (company) — Registrant
- RLMD (company) — Trading Symbol
- The NASDAQ Capital Market (company) — Exchange
- September 17, 2025 (date) — Date of earliest event reported
- 2222 Ponce de Leon Blvd., Floor 3, Coral Gables, FL 33134 (location) — Address of principal executive offices
FAQ
What is the new address for Relmada Therapeutics, Inc.'s principal executive offices?
The new address for Relmada Therapeutics, Inc.'s principal executive offices is 2222 Ponce de Leon Blvd., Floor 3, Coral Gables, FL 33134.
What is the trading symbol for Relmada Therapeutics, Inc. common stock?
The trading symbol for Relmada Therapeutics, Inc. common stock is RLMD.
On which exchange is Relmada Therapeutics, Inc. common stock traded?
Relmada Therapeutics, Inc. common stock is traded on The NASDAQ Capital Market.
What is the earliest event date reported in this 8-K filing?
The earliest event date reported in this 8-K filing is September 17, 2025.
Does this filing indicate any changes in Relmada Therapeutics' business operations or financial status?
No, this filing primarily serves to update the company's principal executive office address and does not indicate changes in business operations or financial status.
Filing Stats: 515 words · 2 min read · ~2 pages · Grade level 10.5 · Accepted 2025-09-17 07:30:55
Key Financial Figures
- $0.001 — nge on which registered Common stock, $0.001 par value per share RLMD The NASDAQ
Filing Documents
- ea0257659-8k_relmada.htm (8-K) — 28KB
- ea025765901ex99-1_relmada.htm (EX-99.1) — 50KB
- ex99-1_001.jpg (GRAPHIC) — 612KB
- ex99-1_002.jpg (GRAPHIC) — 711KB
- ex99-1_003.jpg (GRAPHIC) — 600KB
- ex99-1_004.jpg (GRAPHIC) — 225KB
- ex99-1_005.jpg (GRAPHIC) — 884KB
- ex99-1_006.jpg (GRAPHIC) — 642KB
- ex99-1_007.jpg (GRAPHIC) — 449KB
- ex99-1_008.jpg (GRAPHIC) — 524KB
- ex99-1_009.jpg (GRAPHIC) — 847KB
- ex99-1_010.jpg (GRAPHIC) — 593KB
- ex99-1_011.jpg (GRAPHIC) — 796KB
- ex99-1_012.jpg (GRAPHIC) — 743KB
- ex99-1_013.jpg (GRAPHIC) — 590KB
- ex99-1_014.jpg (GRAPHIC) — 611KB
- ex99-1_015.jpg (GRAPHIC) — 543KB
- ex99-1_016.jpg (GRAPHIC) — 245KB
- ex99-1_017.jpg (GRAPHIC) — 457KB
- ex99-1_018.jpg (GRAPHIC) — 306KB
- ex99-1_019.jpg (GRAPHIC) — 350KB
- ex99-1_020.jpg (GRAPHIC) — 410KB
- ex99-1_021.jpg (GRAPHIC) — 514KB
- ex99-1_022.jpg (GRAPHIC) — 432KB
- ex99-1_023.jpg (GRAPHIC) — 173KB
- ex99-1_024.jpg (GRAPHIC) — 468KB
- ex99-1_025.jpg (GRAPHIC) — 724KB
- ex99-1_026.jpg (GRAPHIC) — 399KB
- ex99-1_027.jpg (GRAPHIC) — 82KB
- ex99-1_028.jpg (GRAPHIC) — 308KB
- ex99-1_029.jpg (GRAPHIC) — 356KB
- ex99-1_030.jpg (GRAPHIC) — 94KB
- ex99-1_031.jpg (GRAPHIC) — 69KB
- ex99-1_032.jpg (GRAPHIC) — 531KB
- 0001213900-25-088360.txt ( ) — 21316KB
- rlmd-20250917.xsd (EX-101.SCH) — 3KB
- rlmd-20250917_lab.xml (EX-101.LAB) — 33KB
- rlmd-20250917_pre.xml (EX-101.PRE) — 22KB
- ea0257659-8k_relmada_htm.xml (XML) — 4KB
01 Regulation
Item 7.01 Regulation FD Disclosure. On September 17, 2025, Relmada Therapeutics, Inc. (the "Company") updated its corporate presentation, a copy of which is furnished herewith as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated into this Item 7.01 by reference. In accordance with General Instruction B.2 of Form 8-K, the information in this Item 7.01 of this Current Report on Form 8-K, including the information set forth in Exhibit 99.1, is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Exchange Act, nor shall it be deemed incorporated by reference in any filing under the Securities Act or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
01. Financial
Item 9.01. Financial (d) Exhibits Exhibit No. Description 99.1* Corporate Presentation dated September 17, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) * Furnished herewith. 1
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: September 17, 2025 RELMADA THERAPEUTICS, INC. By: /s/ Sergio Traversa Name: Sergio Traversa Title: Chief Executive Officer 2